| Literature DB >> 29908304 |
Amy J Clippinger1, David Allen2, Holger Behrsing3, Kelly A BéruBé4, Michael B Bolger5, Warren Casey6, Michael DeLorme7, Marianna Gaça8, Sean C Gehen9, Kyle Glover10, Patrick Hayden11, Paul Hinderliter12, Jon A Hotchkiss13, Anita Iskandar14, Brian Keyser15, Karsta Luettich14, Lan Ma-Hock16, Anna G Maione11, Patrudu Makena15, Jodie Melbourne17, Lawrence Milchak7, Sheung P Ng18, Alicia Paini19, Kathryn Page20, Grace Patlewicz21, Pilar Prieto19, Hans Raabe3, Emily N Reinke22, Clive Roper23, Jane Rose24, Monita Sharma17, Wayne Spoo15, Peter S Thorne25, Daniel M Wilson13, Annie M Jarabek26.
Abstract
New approaches are needed to assess the effects of inhaled substances on human health. These approaches will be based on mechanisms of toxicity, an understanding of dosimetry, and the use of in silico modeling and in vitro test methods. In order to accelerate wider implementation of such approaches, development of adverse outcome pathways (AOPs) can help identify and address gaps in our understanding of relevant parameters for model input and mechanisms, and optimize non-animal approaches that can be used to investigate key events of toxicity. This paper describes the AOPs and the toolbox of in vitro and in silico models that can be used to assess the key events leading to toxicity following inhalation exposure. Because the optimal testing strategy will vary depending on the substance of interest, here we present a decision tree approach to identify an appropriate non-animal integrated testing strategy that incorporates consideration of a substance's physicochemical properties, relevant mechanisms of toxicity, and available in silico models and in vitro test methods. This decision tree can facilitate standardization of the testing approaches. Case study examples are presented to provide a basis for proof-of-concept testing to illustrate the utility of non-animal approaches to inform hazard identification and risk assessment of humans exposed to inhaled substances.Entities:
Keywords: Acute inhalation toxicity; Adverse outcome pathway; Aggregate exposure pathway; Dosimetry; Ex vivo; In silico; In vitro; Integrated approach to testing and assessment (IATA); Quantitative structure-activity relationships (QSAR); Risk assessment
Mesh:
Year: 2018 PMID: 29908304 PMCID: PMC6760245 DOI: 10.1016/j.tiv.2018.06.009
Source DB: PubMed Journal: Toxicol In Vitro ISSN: 0887-2333 Impact factor: 3.500